Celcuity Inc是一家临床阶段生物技术公司。该公司正在寻求通过实施综合治疗(Rx)和伴随诊断(CDx)策略来延长癌症患者的生命。它的治疗工作集中在开发分子靶向治疗,以解决CELsignia同伴诊断可以识别的相同癌症驱动因素。该公司的主要候选治疗药物是gedatolisib,一种有效、可逆的双抑制剂,选择性靶向PI3K的所有I类亚型和雷帕霉素(mTOR)的哺乳动物靶向。其作用机制和药代动力学特性与单独或联合靶向PI3K或mTOR的其他研究治疗有很大区别。Gedatolisib最初的临床开发计划侧重于激素受体阳性(HR+)、HER2阴性、晚期或转移性乳腺癌患者的治疗。该公司的其他临床开发计划侧重于各种其他肿瘤类型。
名称 | 标题 | 任期 | 年龄 |
|---|---|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & CEO | 2012 | 64 |
| Lance G. Laing | Co-Founder, Chief Science Officer, VP, Secretary & Director | 2012 | 64 |
| Leo T. Furcht | Independent Director | 2019 | 79 |
| David F. Dalvey | Independent Director | 2014 | 68 |
| Richard J. Nigon | Independent Director | 2017 | 78 |
| Edward Greeno | Member of Scientific Advisory Board | - | - |
| Sara A. Hurvitz | Member of Scientific Advisory Board | - | - |
| Carol Lange | Member of Scientific Advisory Board | - | - |
| Benita Katzenellenbogen | Member of Scientific Advisory Board | - | - |
| Ronald C. McGlennen | Member of Scientific Advisory Board | - | - |
| John Katzenellenbogen | Member of Scientific Advisory Board | - | - |
| Mothaffar F. Rimawi | Member of Scientific Advisory Board | 2019 | - |
| Lee S. Schwartzberg | Member of Scientific Advisory Board | 2019 | - |
| Mark D. Pegram | Member of Scientific Advisory Board | - | - |
| Stanley M. Marks | Member of Scientific Advisory Board | - | 79 |
| Manfred Auer | Member of Scientific Advisory Board | - | - |
| Adam M. Brufsky | Member of Scientific Advisory Board | - | - |
| Richard E. Buller | Independent Director | 2019 | 76 |
| Bora Lim | Member of Scientific Advisory Board | 2020 | - |
| Ben Ho Park | Member of Scientific Advisory Board | 2020 | - |
| Hung Khong | Member of Scientific Advisory Board | 2021 | - |
| Alberto Montero | Member of Scientific Advisory Board | 2021 | - |
| Polly A. Murphy | Independent Director | 2022 | 61 |
| Charles R. Romp | Director | 2026 | 57 |